Privacy Policy

This Web Site is owned by AMAG Pharmaceuticals, Inc. Lexington, Massachusetts, USA ("AMAG") and operated either by us or by a third party with whom we have contracted to host this Web Site for us. The information provided on this Web Site is for general informational and educational purposes only.



AMAG Pharmaceuticals, Inc. Privacy Policy

AMAG respects the privacy of the visitors to the Site. This Privacy Policy is intended to inform you of our policies and practices regarding the collection, use, and disclosure of any Personal Information you submit to us through the Site. By submitting Personal Information through the Site, you agree to the terms of this Privacy Policy and you expressly consent to the processing of your Personal Information according to this Privacy Policy.

BY VIEWING AND ACCESSING THE AMAG WORLD WIDE WEB SITE, WWW.AMAGPHARMA.COM WEB SITE, OR ANY OF OUR WEB SITES, INCLUDING WITHOUT LIMITATION WWW.FERAHEME.COM AND WWW.IDANEMIA.COM, (EACH A “SITE” or "WEB SITE"), YOU (“YOU” OR “YOUR”) REPRESENT THAT YOU HAVE READ AND UNDERSTOOD THIS ENTIRE PRIVACY POLICY (“PRIVACY POLICY”) AND YOU AGREE TO ALL THE TERMS OF THIS PRIVACY POLICY. IF YOU DO NOT CONSENT TO THIS PRIVACY POLICY IN ITS ENTIRETY, YOUR SOLE AND EXCLUSIVE REMEDY IS TO IMMEDIATELY CEASE USE OF THE SITE.

To make our Site more useful to you, our servers (which may be hosted by a third party service provider) collect Personal Information from you, including browser type, operating system, Internet Protocol (IP) address (a number that is automatically assigned to your computer when you use the Internet, which may vary from session to session), domain name, and/or a date/time stamp for your visit. AMAG also uses customized software, which may include software that passively collects certain Anonymous Data about your visits to the Site, such as your IP address, the browser version your computer is operating and the time of day you access the Site. We also may use Cookies (as defined below) and navigational data like Uniform Resource Locators (URL) to gather information regarding the date and time of your visit and the solutions and information for which you searched and which you viewed. Like most Internet services, we automatically gather this Personal Information and store it in log files each time you visit our Web Site or access your account on our network. “Cookies” are small pieces of information that a Web Site sends to your computer's hard drive while you are viewing a Web Site. We may use both session Cookies (which expire once you close your web browser) and persistent Cookies (which stay on your computer until you delete them) to provide you with a more personal and interactive experience on our Web Site. Persistent Cookies can be removed by following Internet browser help file directions. If you choose to disable Cookies, some areas of our Web Site may not work properly. AMAG reserves the right to reproduce, use, disclose, and distribute Anonymous Data for any purpose.

Creation of Anonymous Data. We may create Anonymous Data records from Personal Information by excluding information (such as your name) that make the data personally identifiable to you. We use this Anonymous Data to analyze request and usage patterns so that we may enhance the content of our Site and services and improve Site navigation. We reserve the right to use and disclose Anonymous Data to Third Party Companies in its discretion.

Feedback. If you provide feedback on any of our products or related services to us, we may use such feedback for any purpose, provided we will not associate such feedback with your Personal Information. We will collect any information contained in such communication and will treat the Personal Information in such communication in accordance with this Privacy Policy.

Affiliates. Although we currently do not have a parent company, any subsidiaries, joint ventures, or other companies under a common control (collectively, “Affiliates”), we may in the future. We may share some or all of your Personal Information with these Affiliates, in which case we will require our Affiliates to honor this Privacy Policy. If another company acquires our company or our assets, that company will possess the Personal Information collected by it and us and will assume the rights and obligations regarding your Personal Information as described in this Privacy Policy.

Other Disclosures. Regardless of any choices you make regarding your Personal Information (as described below), We may disclose Personal Information if it believes in good faith that such disclosure is necessary to (a) comply with relevant laws or to respond to subpoenas or warrants served on Company; or (b) protect or defend the rights or property of Company or users of the products or related services.

Disclosure to Third Party Service Providers. Except as otherwise stated in this policy, we do not generally sell, trade, share, or rent the Personal Information collected from our services to other entities. However, we may share your Personal Information with third party service providers to respond to your inquiries and to send you information about our products. These third party service providers are required not to use your Personal Information other than to provide the services requested by Company. You expressly consent to the sharing of your Personal Information with our contractors and other service providers for the sole purpose of providing services to you.

Disclosure to Third Party Companies. We may enter into agreements with Third Party Companies. A Third Party Company may want access to Personal Information that we collect. As a result, we may disclose your Personal Information to a Third Party Company; however, we will not disclose your Personal Information to Third Party Companies for the Third Party Companies' own direct marketing purposes, unless you have “opted-in” by following the instructions we provide to allow such disclosure. If you have opted-in to receive e-mail communications from a Third Party Company and later wish to discontinue receipt of these e-mails, please contact the Third Party Company directly to update your preferences. The privacy policies of our Third Party Companies may apply to the use and disclosure of your Personal Information that we collect and disclose to such Third Party Companies. Because we do not control the privacy practices of our Third Party Companies, you should read and understand their privacy policies.

We offer you choices regarding the collection, use, and sharing of your Personal Information. We will periodically send you free newsletters and e-mails that directly promote the use of our Site or the purchase of our products or services and may contain advertisements for Third Party Companies. When you receive newsletters or promotional communications from us, you may indicate a preference to stop receiving further communications from us and you will have the opportunity to “opt-out” by following the unsubscribe instructions provided in the e-mail you receive or by contacting us directly (please see contact information below). Should you decide to opt-out of receiving future mailings, we may share your e-mail address with third parties to ensure that you do not receive further communications from third parties. Despite your indicated e-mail preferences, we may send you notices of any updates to our Terms of Use or Privacy Policy.

The Site contains links to other Web Sites and their affiliates. AMAG is not responsible for the content or privacy practices of any other “linked” or “affiliated” Sites which you might access through our Site. You should read their privacy policies and terms of use carefully before providing them with Personal Information. When you click on such a link, you will leave our Site and go to another Site. During this process, another entity may collect Personal Information or Anonymous Data from you. We have no control over, do not review, and cannot be responsible for, these outside Web Sites or their content. Please be aware that the terms of this Privacy Policy do not apply to these outside Web Sites or content, or to any collection of data after you click on links to such outside Web Sites.

We may also receive Personal and/or Anonymous Data about you from other sources like telephone or fax, or from companies that provide our products or services by way of a co-branded or private-labeled Web Site or companies that offer their products and/or services on our Web Site (“Third Party Companies”). We may add this information to the information we have already collected from you via our Web Site in order to improve the products and services we provide.

This Privacy Policy is subject to occasional revision, and if we make any substantial changes in the way we use your Personal Information, we will notify you by sending you an e-mail to the last e-mail address you provided to us and/or by prominently posting notice of the changes on our Web Site. Any material changes to this Privacy Policy will be effective upon the earlier of thirty (30) calendar days following our dispatch of an e-mail notice to you or thirty (30) calendar days following our posting of notice of the changes on our Site. These changes will be effective immediately for new users of our Web Site, products or related services. Please note that at all times you are responsible for updating your Personal Information to provide us with your most current e-mail address. In the event that the last e-mail address that you have provided us is not valid, or for any reason is not capable of delivering to you the notice described above, our dispatch of the e-mail containing such notice will nonetheless constitute effective notice of the changes described in the notice. In any event, changes to this Privacy Policy may affect our use of Personal Information that you provided us prior to our notification to you of the changes. If you do not wish to permit changes in our use of your Personal Information, you must notify us prior to the effective date of the changes that you wish to deactivate your account with us. Continued use of our Web Site, products, or related services, following notice of such changes shall indicate your acknowledgement of such changes and agreement to be bound by the terms and conditions of such changes.

This Privacy Policy was last revised on June 23, 2009.

 

Important Safety Information
Indication and contraindications

Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme is contraindicated in patients with evidence of iron overload, known hypersensitivity to Feraheme or any of its components, and patients with anemia not caused by iron deficiency.

Warnings and precautions

In clinical studies, serious hypersensitivity reactions were reported in 0.2% (3/1,726) of subjects receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of subjects. Patients should be observed for signs and symptoms of hypersensitivity for at least 30 minutes following Feraheme injection and the drug should only be administered when personnel and therapies are readily available for the treatment of hypersensitivity reactions. 1.9% (33/1,726) of Feraheme-treated subjects experienced hypotension. Please monitor for signs and symptoms of hypotension following each Feraheme injection. Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme. As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.

Adverse reactions

In clinical trials, the most commonly occurring adverse reactions in Feraheme treated patients versus oral iron treated patients reported in ≥2% of chronic kidney disease patients were diarrhea (4.0% vs. 8.2%), nausea (3.1% vs. 7.5%), dizziness (2.6% vs. 1.8%), hypotension (2.5% vs. 0.4%), constipation (2.1% vs. 5.7%) and peripheral edema (2.0% vs. 3.2%). In clinical trials, adverse reactions leading to treatment discontinuation and occurring in 2 or more Feraheme-treated patients included hypotension, infusion site swelling, increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis, pruritus, chronic renal failure, and urticaria.

Please see full Prescribing Information for Feraheme.